Abstract
Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Current Cancer Therapy Reviews
Title:Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Volume: 11 Issue: 2
Author(s): Rony Benson, Supriya Mallick, K.P. Haresh, P.K. Julka and G.K. Rath
Affiliation:
Keywords: Bladder carcinoma, chemo-radiotherapy, locally advanced.
Abstract: Urinary bladder carcinoma is estimated to be the ninth most common cause of cancer worldwide. The treatment of bladder carcinoma is an area of active research owing to lack of evidence of any treatment modality. Traditionally surgery, cystectomy, was considered the cornerstone of therapy. However, the morbidity of such approach has paved for bladder preservation approach with radiation in combination with chemotherapy. The use of transurethral resection of bladder tumor along with radiation and chemotherapy helps patients to have a functional bladder without compromising survival. Adjuvant radiation is an underutilized treatment modality. In the present era availability of sophisticated radiation technique allows delivery of radiation without increasing toxicity. Hence, adjuvant radiation may be used for patients with R1 resection and lymph node positive disease alone or in combination with chemotherapy. Radiation also appears a valuable treatment option for palliation in bladder tumor. We herein intend to review the present place of radiation in the management of transitional cell carcinoma of urinary bladder.
Export Options
About this article
Cite this article as:
Benson Rony, Mallick Supriya, Haresh K.P., Julka P.K. and Rath G.K., Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203201
DOI https://dx.doi.org/10.2174/1573394711666151022203201 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids
Current Pharmaceutical Biotechnology Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Current Concepts on the Management of Chordoma
Current Drug Therapy Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry The Complex Biology of FOXO
Current Drug Targets Gene Delivery for Cancer Therapy
Current Drug Delivery